Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: Report from a phase I study

Journal of Experimental and Clinical Cancer Research

Volumn 25, Issue 2, 2006, Pages 201-206

  Burgdorf, Stefan K ^a   Fischer, A ^a   Claesson, M H ^b   Kirkin, A F ^c   Dzhandzhugazyan, K N ^c   Rosenberg, J ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c DanDrit Biotech A/S   (Denmark)

Author keywords

Cancer antigens; Cancer vaccines; Dendritic cell

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL LYSATE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-4; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINATION;

EID: 33746338549     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ridgway D.: The first 1000 dendritic cell vaccinees. Cancer Invest. 21:873-86, 2003.
2. Rodriguez A., Regnault A., Kleijmeer M., et al.: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1:362-8, 1999.
3. Lizee G., Basha G., Tiong J., et al.: Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat. Immunol. 4:1065-73, 2003.
4. Vieweg J., Jackson A.: Modulation of antitumor responses by dendritic cells. Springer Semin. Immunopathol. 26:329-41, 2005.
5. Cranmer L.D., Trevor K.T., Hersh E.M.: Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother. 53:275-306, 2004.
6. Fong L., Hou Y., Rivas A., et al.: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98:8809-14, 2001.
7. Huber C.H., Wolfel T.: Immmunotherapy of cancer: from vision to standard clinical practice. J. Cancer Res. Clin. Oncol. 130:367-74, 2004.
8. Rains N., Cannan R.J., Chen W., et al.: Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 48:347-51, 2001.
9. Schuler-Thurner B., Schultz E.S., Berger T.G., et al.: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:1279-88, 2002.
10. Yamanaka R., Homma J., Yajima N., et al.: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin. Cancer. Res. 11:4160-7, 2005.
11. Nair S., McLaughlin C., Weizer A., et al.: Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171:6275-82, 2003.
12. Kirkin A.F., Petersen T.R., Olsen A.C., et al.: Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol. Immunother. 41:71-81, 1995.
13. Kirkin A.F., Thor S.P., Hansen M.R., et al.: Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones. Cancer Immunol. Immunother. 48:239-46, 1999.
14. Romani N., Gruner S., Brang D., et al.: Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83-93, 1994.
15. Thurner B., Roder C., Dieckmann D., et al.: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 223:1-15, 1999.
16. Bjorner J.B., Thunedborg K., Kristensen T.S., et al.: The Danish SF-36 Health Survey: translation and preliminary validity studies. J. Clin. Epidemiol. 51:991-9, 1998.
17. Ware J.E.Jr., Sherbourne C.D.: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30:473-83, 1992.
18. De Plaen E., Arden K., Traversari C., et al.: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360-9, 1994.
19. Thor S.P., Kirkin A.F., Seremet T., et al.: Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int. J. Cancer 70:582-6, 1997.
20. Gerhardt A., Usener D., Keese M., et al.: Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. Cancer Lett. 208:197-206, 2004.
21. Scanlan M.J., Gure A.O., Jungbluth A.A., et al.: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188:22-32, 2002.
22. Thurner B., Haendle I., Roder C., et al.: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669-78, 1999.
23. Iwashita Y., Tahara K., Goto S., et al.: A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol. Immunother. 52:155-61, 2003.
24. Morse M.A., Clay T.M., Hobeika A.C., et al.: Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 11:3017-24, 2005.
25. Ishikawa A., Motohashi S., Ishikawa E., et al.: A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11:1910-7, 2005.
26. Caruso D.A., Orme L.M., Amor G.M., et al.: Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 103:1280-91, 2005.
27. Di Nicola M., Carlo-Stella C., Mortarini R., et al.: Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin. Cancer. Res. 10:5381-90, 2004.
28. Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int. 94:412-8, 2004.
29. Caruso D.A., Orme L.M., Neale A.M., et al.: Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncol. 6:236-46, 2004.
30. Hersey P., Menzies S.W., Halliday G.M., et al.: Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol. Immunother. 53:125-34, 2004.
31. Yamanaka R., Abe T., Yajima N., et al.: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br. J. Cancer 89:1172-9, 2003.